亚洲成av人在线观看网站-国产内射老熟女aaaa-中文字幕日韩精品亚洲一区-亚洲人成手机电影网站

About Berry Genomics

Founded in May 2010, Berry Genomics is a leading company in clinical genomics and life science in China. Berry Genomics is dedicated to research, development and commercialization of genetic test technologies in clinical applications. Berry Genomics aims to assist accurate diagnosis of diseases throughout the full human life circle, and to improve human health.

As a company with strong R&D capability, Berry Genomics pioneered the first NGS-based genetic test, NIPT, in China back in 2010. The company currently provides NGS- based tests for many genetic diseases and cancers from preconception to adulthood. Berry Genomics is leading in the clinical study of early clinical detection of liver cancer in the world. Exploring the use of the third-generation sequencing technology in both clinical field and scientific study is ongoing.

Berry Genomics has around 1500 employees dedicating to developing products and providing services for over 6000 organizations and facilities home and abroad, including hospitals, research institutions, universities and corporations.

Berry Genomics has been listed on A-share market in China since 2017 under the stock code: 000710.

Vision

Being the top trustworthy partner in genomics

Mission

Innovate for the future, improve human well-being

Strategy

Focus on the clinical applications, base on the R&D,

Moving forward by innovation, gain trust with quality

Company footprints

Berry Genomics invests in genomic industry based on its market insights and forward thinking, ranging from clinical research, technology development, medical device manufacturing, clinical testing, genomic database integration, professional genetic counseling, to consumer genomics, and gene therapy.

The headquarter is located in Beijing.

Berry Genomics owns 7 certified clinical laboratories located in Beijing, Shanghai, Chengdu, Chongqing, Qingdao, Fuzhou, and Hong Kong.

Berry Genomics owns a licensed medical device manufacturing facility in Hangzhou.

In 2013, Xcelom Limited, a subsidiary dedicating to serve the overseas genetic testing market, was established in Hong Kong.

In 2015, teaming up with Professor Tony Mok of CUHK, Berry Genomics established Sanomics Limited, a leading oncology company in Hong Kong, providing safe and rapid cancer genetic testing.

In 2017, Berry Oncology was established, specializing in cancer diagnosis and early detection.

In 2017, Berry Genomics broke ground for its digital life science park in Fuzhou. With more than 260,000 square meters, the park is designed to cover every segment of gene industry, from technology development to medical device manufacturing, from genetic testing to disease treatment.

In 2018, Berry Genomics became one of the investors in CircleDNA, a consumer genomic company.

Founders

  • Yang Gao
    Dr. Yang Gao, Chairman, Berry Genomics, a pioneer in NGS research and applications in China
  • Daixing Zhou
    Dr. Daixing Zhou, Chief Scientist, Berry Genomics, one of the major contributors to NGS in the world. Dr. Zhou is widely recognized as the pioneer of NIPT in China.
  • Ying Hou
    Mrs. Ying Hou, Vice President, Berry Genomics. Mrs. Hou is an expert in the NGS market in China.
Business

Berry Genomics regards innovation as its core value to power the company. Berry Genomics is committed to providing high-quality and cost-effective genetic tests to patients, and value-added services to the scientific communities.

Berry Genomics currently provides genetic test services to over 2000 hospitals in China mainly in the area of reproductive health, genetic disease and cancer. Up to now, Berry Genomics has served more than 500 million patients in China in total.

In parallel, more than 100 top Chinese hospitals have built their clinical laboratories based on the products and workflow provided by Berry Genomics. With Berry Genomics’ supports, these organizations can run their genetic tests autonomously.

Berry Genomics’ contract service team has supported more than 10,000 science research programs of over 2000 hospitals, institutions, universities and companies.

The integrated business model of testing service and product providing is well proved to meet the diversified market needs in China.

Product

Berry Genomics is committed to investing in R&D to drive the development and validation of new technologies and diagnostic tests. The R&D achievements have been granted domestic and foreign patents. All patented and other core technologies are put into use in the products and testing services. In the reproductive genetics market, Berry Genomics is recognized as the leading provider of quality products and services by the customers. In the oncology testing market, Berry Oncology’s sensitive liquid biopsy and cancer early detection technologies are highly acknowledged by the customers and partners.

In 2015, Berry Genomics’ sequencer, NextSeq CN500, and its NIPT reagent obtained IVD license from the National Medical Products Administration (NMPA), which was among the first batch of licenses of its kind in China. In 2019, NextSeq CN500 got NMPA’s official approval to extend its clinical testing scope from NIPT only to multi-human diseases including genetic diseases and cancers. And there are more products in the queue of license application.

Key Publications

Liang D, Cram D S, Tan H, et al. Clinical utility of noninvasive prenatal screening for expanded chromosome disease syndromes[J]. Genetics in Medicine, 2019, 21(9): 1998-2006.

Lv W, Li Z, Wei X, et al. Noninvasive fetal genotyping in pregnancies at risk for PKU using a comprehensive quantitative cSMART assay for PAH gene mutations: a clinical feasibility study[J]. BJOG: An International Journal of Obstetrics & Gynaecology, 2019, 126(12): 1466-1474.

Prospective chromosome analysis of 3429 amniocentesis samples in China using copy number variation sequencing. American Journal of Obstetrics and Gynecology, 2018;219(3): 287.e1-287.e18.

Performance of a quantitative assay for noninvasive prenatal diagnosis of autosomal recessive hearing loss caused by GJB2 and SLC26A4 mutations. Genetics in Medicine, 2017;19:1306-1316.

Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma. Journal of Molecular Diagnostics. 2016. pii: S1525-1578(16)30220-3.

Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology. Oncotarget. 2016;7(31):50477-50489.

Non-invasive prenatal testing for Wilson Disease using circulating Single Molecule Amplification and Re-sequencing Technology (cSMART). Clinical Chemistry, 2015;61:172-181.

More Information

For more information, please contact Miss. Aima Shi at shijiajia821@berrygenomics.com

shijiajia821@berrygenomics.com
主站蜘蛛池模板: 国产男女色诱视频在线播放| 强制高潮18xxxxhd日韩| 亚洲va中文字幕无码一二三区| 蜜桃av抽搐高潮一区二区| 色欲色香天天天综合vvv| 欧美激情做真爱牲交视频| 日本动态120秒免费| 又粗又大内射免费视频小说| 日本一区二区三区爆乳| 日韩av无码一区二区三区| 国产成人综合久久精品推最新| 无码av中文一区二区三区桃花岛| 成视频年人黄网站免费视频| 亚洲av无码兔费综合| 500av导航大全精品| 色猫咪av在线网址| 国产卡一卡二卡三免费入口| 婷婷五月综合缴情在线视频| 国产良妇出轨视频在线观看| 女人色熟女乱| 亚洲乱码日产一区三区| 国产乱码卡一卡2卡三卡四| 天堂资源官网在线资源| 国产亚洲精品成人aa片新蒲金| 久久人与动人物a级毛片| 色哟哟国产精品免费观看| 久久精品噜噜噜成人av| 久久精品国产精品| 国产伦子系列沙发午睡| 国产裸体歌舞一区二区| 亚洲人成亚洲人成在线观看| 成全电影大全免费观看完整视频 | 无遮挡又黄又刺激又爽的视频| 久久久久噜噜噜亚洲熟女综合| 国产suv精二区| 亚洲小说图片| 色欲精品国产一区二区三区av| 日本熟妇浓毛| 人妻丰满熟妇无码区免费| 亚洲av综合色区无码二区爱av| 中文av无码人妻一区二区三区|